Clinical trials: Prosthetic Heart Valve Thrombosis
Thrombolysed
To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve Thrombosis
Annual incidence of PVT for mechanical valves is 0.3 - 1.3% patient-yrs. First postoperative year is marked by a 24% incidence of thrombosis.
- Trial name
- PHVT (NCT07360717)
- Testing
- Alteplase, streptokinase
- Where
- India
- Volunteers
- 100 people
- Sponsor
- U. N. Mehta Institute of Cardiology and Research Center
Atrial Fibrillation, Venous Thrombosis
Safer Warfarin Treatment
The study is a national multicenter prospective observational study, including 200 patients. The main purpose of this study is to explore in more detail the influence of genetic variability (CYP enzymes and vitamin K dependent…
- Conditions
- Atrial Fibrillation, Venous Thrombosis, Pulmonary Embolism, Heart Valve Prosthesis
- Trial name
- CYKOWAR (NCT01042067)
- Testing
- Blood specimens (whole blood, serum, plasma)
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
Prosthetic Valve Thrombosis
A Study Comparing a New Dosing Regimen of Clot-dissolving Drug for Mechanical Heart Valves Which Show Clots
The optimal dosage and duration of administration of clot-dissolving medications for the treatment of patients with mechanical heart valves with clots is not known.
- Trial name
- RAFT-PVT (NCT00232622)
- Testing
- Streptokinase
- Volunteers
- 120 people
- Sponsor
- All India Institute of Medical Sciences
Aortic Valve Disease, Artificial Heart Valves
Post-market Clinical Monitoring of the Safety and Efficacy of the Aortic Valve Bioprothesis
The goal of this multicenter prospective cohort study is to evaluate the long-term safety and efficacy of clinical outcomes of aortic valve replacement using the "TiAra" prosthesis with or without concomitant procedures.
- Trial name
- TiAra (NCT05998694)
- Where
- Russia
- Volunteers
- 2,000 people
- Sponsor
- Closed Joint-Stock Company NeoCor
Cardiac Arrhythmias, Hemorrhage
Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation
Approximately 2 million patients in North America are currently treated with the blood thinner warfarin. These patients have every year more than 200,000 invasive procedures, for which warfarin must be stopped to avoid bleeding…
- Conditions
- Cardiac Arrhythmias, Hemorrhage, Thromboembolism
- Trial name
- PACEBRIDGE (NCT02094157)
- Testing
- Tapered warfarin regimen, Bridged regimen Low-molecular-weight heparin
- Where
- 2 sites in Canada
- Volunteers
- 173 people
- Sponsor
- McMaster University
Valvular Heart Disease Patients
Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves
Warfarin is the standard anticoagulant used for patients with mechanical heart valves; however, its use is complicated by a narrow therapeutic window, frequent drug and dietary interactions, and the need for regular international…
- Trial name
- NCT07456085
- Testing
- Rivoroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Rawalpindi Institute of Cardiology
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine.
- Conditions
- Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- thrombEVAL (NCT01809015)
- Where
- Germany
- Volunteers
- 2,318 people
- Sponsor
- Johannes Gutenberg University Mainz